Silexion Therapeutics (NASDAQ:SLXN) Trading Up 6.6% – Should You Buy?

Posted by Scott Moore on Feb 8th, 2026

Shares of Silexion Therapeutics Corp (NASDAQ:SLXN – Get Free Report) shot up 6.6% during trading on Friday . The stock traded as high as $1.7258 and last traded at $1.61. 22,904 shares traded hands during trading, a decline of 47% from the average session volume of 43,386 shares. The stock had previously closed at $1.51.

Analyst Ratings Changes

Several research analysts have issued reports on SLXN shares. Litchfield Hills Research began coverage on shares of Silexion Therapeutics in a research report on Monday, December 15th. They issued a “buy” rating on the stock. Zacks Research upgraded Silexion Therapeutics to a “hold” rating in a report on Tuesday, December 16th. Finally, Wall Street Zen downgraded Silexion Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $75.00.

Get Our Latest Report on SLXN

Silexion Therapeutics Stock Up 6.6%

The firm has a market cap of $5.03 million, a PE ratio of -0.15 and a beta of -0.03. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.97 and a quick ratio of 3.97. The business has a fifty day moving average price of $2.28 and a two-hundred day moving average price of $4.26.

Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($2.88) EPS for the quarter, topping analysts’ consensus estimates of ($3.40) by $0.52.

Silexion Therapeutics Company Profile

(Get Free Report)

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.